Strides partners on oral repurposed med to treat COVID‐19

21 June 2021
covid_big

The Singapore unit of Indian drugmaker Strides Pharma Science (BSE: 532531) has entered into an exclusive partnership with USA-based Ennaid Therapeutics to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms. Initial tests show antiviral activity effective against SARS CoV‐2, the virus that causes COVID‐19, by inhibiting 90% of the virus' replication in vitro studies.

Ready to file for EUA in USA

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical